Deramciclane has high affinity for 5-HT2A and 5-HT2C receptors. It acts as an antagonist in both receptor subtypes and has inverse agonist properties for 5-HT2C receptors, but no direct stimulant agonists.
Iferanserin (S-MPEC) is a selective antagonist of the 5-HTreceptor (serotonin receptor) with an affinity for 5-HT2Areceptors. Iferanserin has the potential for internal hemorrhoid disease treatment.
Arotinolol is a nonselective α β-adrenergic receptor blocker and a vasodilating β-blocker. Arotinolol also shows potency for inhibiting the binding of the radioligand 125I-ICYP to 5HT1B-serotonergic receptor sites. It is an antihypertensive agent.
5-HT6 5-HT2Areceptor ligand-1 (compound 33) is a dual antagonist for the 5-HT6 and 5-HT2Areceptors. It exhibits a K i value of 2 nM and 11 nM for the respective receptors. This compound holds promise for research in neurological and psychiatric disorders [1].